The longest ever randomised controlled trial of insulin glargine: study design and HbA(1c) findings.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2020
   Pooled it
2. Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?Frontiers in endocrinology · 2017
   Review
3. Diabetes Mellitus and Risk of Hepatocellular Carcinoma.BioMed research international · 2017
   Review
4. Looking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism.Scientific reports · 2016
   Article
5. Diabetes and cancer: a consensus report.Diabetes care · 2010
   Article

Corrections and comments

• Comment on
  Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.2009

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as